Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Join SI Premium – FREE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.05), $0.02 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $28 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- New FarmBot Tech Research Finds US Precision Agriculture Use Fell From 27% to 22% as Farm Bankruptcies Rose 46%
- Uber Inc. (UBER) PT Lowered to $90 at BTIG
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
